Biomedical Engineering Reference
In-Depth Information
198. Galili, U.; Wigglesworth, K.; Abdel-Motal, U. M. Intratumoral Injection of Alpha-gal Glyco-
lipids Induces Xenograft-like Destruction and Conversion of Lesions Into Endogenous Vac-
cines.
J. Immunol.
2007,
182,
5217-5224.
199. Brody, J. D.; Ai, W. Z.; Czerwinski, D. K.; Torchia, J. A.; Levy, M.; Advan, R. H., et al. In
situ Vaccination with a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II
Study.
J. Clin. Oncol.
2010,
28,
4324-4332.
200. Bourquin, C.; Anz, D.; Zwiorek, K.; Lanz, A. L.; Fuchs, S.; Weigel, S., et al. Targeting CpG
Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immu-
nity.
J. Immunol.
2008,
181,
2990-2998.
201. Eton, O.; Rosenblum, M. G.; Legha, S. S.; Zhang, W.; Jo East, M.; Bedikian, A., et al. Phase
I Trial of Subcutaneous Recombinant Human Interleukin-2 in Patients with Metastatic Mela-
noma.
Cancer
2002,
95,
127-134.
202. Hori, Y.; Stern, P. J.; Hynes, R. O.; Irvine, D. J. Engulfing Tumors with Synthetic Extracellular
Matrices for Cancer Immunotherapy.
Biomaterials
2009,
30,
6757-6767.
203. de Jong, S.; Chikh, G.; Sekirov, L.; Raney, S.; Semple, S.; Klimuk, S., et al. Encapsulation in
Liposomal Nanoparticles Enhances the Immunostimulatory, Adjuvant and Anti-tumor Activ-
ity of Subcutaneously Administered CpG ODN.
Cancer Immunol. Immunother.
2007,
56,
1251-1264.
204. Hanes, J.; Sills, A.; Zhao, Z.; Suh, K. W.; Tyler, B.; DiMeco, F., et al. Controlled Local Deliv-
ery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain
Tumors and Liver Tumors.
Pharm. Res.
2001,
18,
899-906.
205. Hill, H. C.; Conway, T. F., Jr.; Sabel, M. S.; Jong, Y. S.; Mathiowitz, E.; R.B., B., et al. Cancer
Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Fac-
tor-encapsulated Microspheres: Coinduction of Innate and Adaptive Antitumor Immunity and
Cure of Disseminated Disease.
Cancer Res.
2002,
62,
7254-7263.
206. Van Herpen, C. M.; Huijbens, R.; Looman, M.; De Vries, J.; Marres, H.; Van De Ven, J., et al.
Pharmacokinetics and Immunological Aspects of a Phase Ib Study with Intratumoral Admin-
istration of Recombinant Human Interleukin-12 in Patients with Head and Neck Squamous
Cell Carcinoma: A Decrease of T-bet in Peripheral Blood Mononuclear Cells.
Clin. Cancer
Res.
2003,
9,
2950-2956.
207. Liu, H.; Zhu, Z.; Kang, H.; Wu, Y.; Sefan, K.; Tan, W. DNA-based Micelles: Synthesis, Micel-
lar Properties and Size-dependent Cell Permeability.
Chemistry
2010,
16,
3791-3797.
208. Sabel, M. S.; Arora, K.; Su, G.; Mathiowitz, E.; Reineke, J. J.; Chang, A. E. Synergistic Effect
of Intratumoral IL-12 and TNF-a Microspheres: Systemic Anti-tumor Immunity is Mediated
by Both CD8+ CTL and NK Cells.
Surgery
2007,
142,
749-760.
209. Hatzifoti, C.; Bacon, A.; Marriott, H.; Laing, P.; Heath, A. W. Liposomal Co-entrapment of
CD40mAb Induces Enhanced IgG Responses Against Bacterial Polysaccharide and Protein.
PLoS One
2008,
3,
e2368.
210. Klinman, D. M. Immunotherapeutic Uses of CpG Oligodeoxynucleotides.
Nat. Rev. Immunol.
2004,
4,
249-258.
211. Stumbles, P. A.; Himbeck, R.; Frelinger, J. A.; Collins, E. J.; Lake, R. A.; Robinson, B. W.
Cutting Edge: Tumor-specific CTL are Constitutively Cross-armed in Draining Lymph Nodes
and Transiently Disseminate to Mediate Tumor Regression Following Systemic CD40 Activation.
J. Immunol.
2004,
173,
5923-5928.
212. Rakhmilevich, A. L.; Buhtoiarov, I. N.; Malkovsky, M.; Sondel, P. M. CD40 Ligation
In vivo Can Induce T Cell Independent Antitumor Effects Even Against Immunogenic Tumors.
Cancer Immunol. Immunother.
2008,
57,
1151-1160.
